Acamprosate - Confluence Pharmaceuticals

Drug Profile

Acamprosate - Confluence Pharmaceuticals

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Confluence Pharmaceuticals
  • Developer Indiana University
  • Class Alkanesulfonic-acids; Drug withdrawal therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Autistic disorder; Fragile X syndrome

Most Recent Events

  • 23 Mar 2015 Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals enter into an agreement to co-develop and market acamprosate for fragile X syndrome in Europe and the Middle East
  • 15 Oct 2014 Acamprosate - Confluence Pharmaceuticals receives Orphan Drug status for Fragile X syndrome in European Union
  • 25 Mar 2013 Acamprosate - Confluence Pharmaceuticals receives Orphan Drug status for Fragile X syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top